ARTICLE | Clinical News
AK0529: Phase II started
August 22, 2016 7:00 AM UTC
Ark began the double-blind, placebo-controlled, international Phase II VICTOR trial to evaluate single and multiple doses of oral AK0529 in about 80 hospitalized infants with RSV infection. Ark has ex...